Toronto - Delayed Quote CAD

Spectral Medical Inc. (EDT.TO)

0.8400

-0.0400

(-4.55%)

At close: May 12 at 3:56:11 PM EDT

Spectral Medical Announces First Quarter and Provides Corporate Update

Tigris Trial Enrollment completedTopline results expected to be released in August 2025Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter and provided a corporate update. The Company mad

GlobeNewswire 3 days ago

EDTXF
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive

• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has entered into a senior secured promissory

GlobeNewswire 5 days ago

EDTXF
Spectral Medical Completes Tigris Trial Enrollment

Spectral Medical (EDT.TO) on Wednesday said it has completed full enrollment in its Tigris trial, a

PREMIUM
MT Newswires 26 days ago

EDTXF
Spectral Medical Full Year 2024 Earnings: Beats Expectations

Spectral Medical ( TSE:EDT ) Full Year 2024 Results Key Financial Results Revenue: CA$2.29m (up 43% from FY 2023). Net...

Simply Wall St. last month

EDTXF
Spectral Medical Swing to Q4 Loss, Revenue Advances

Spectral Medical (EDT.TO) on Thursday said it swung to a fourth-quarter loss even as revenue advance

PREMIUM
MT Newswires last month

EDTXF
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update

154 patients enrolledTORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2024 and provided a corporate update. The Company made significant progress throughout 2024, both clinically and operationally. Specifically, regarding its Tigris trial, a Phase III

GlobeNewswire last month

EDTXF
Spectral Medical Nearing End of Tigris Trial Patient Enrollment

Spectral Medical (EDT.TO) on Monday said it is nearing the end patient enrollment for its Tigris tri

PREMIUM
MT Newswires 2 months ago

EDTXF
Spectral Medical Provides February Tigris Trial Update

152 patients enrolled TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Strong start to 2025 enrollment: 152

GlobeNewswire 2 months ago

EDTXF
Spectral Medical Provides January Tigris Trial Update

Strong enrollment activity to start 2025146 patients enrolled TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollmen

GlobeNewswire 3 months ago

EDTXF
Spectral Medical Provides December Tigris Trial Update

• 140 patients enrolled TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Strong close to 2024 enrollment wit

GlobeNewswire 4 months ago

EDTXF
Spectral Medical Provides November Tigris Trial Update

• 136 patients enrolled • Company to host Tigris Trial Update Call December 16, 2024 TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic

GlobeNewswire 5 months ago

EDTXF
Spectral Medical Third Quarter 2024 Earnings: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023)

Spectral Medical ( TSE:EDT ) Third Quarter 2024 Results Key Financial Results Revenue: CA$502.0k (up 26% from 3Q 2023...

Simply Wall St. 5 months ago

EDTXF
Hurricane Helene delays Spectral Medical’s confirmatory trial enrolment

Spectral aims to finalise enrolment in early 2025 for its septic shock treatment Toraymyxin.

Clinical Trials Arena 5 months ago

EDTXF
Spectral Medical Announces Third Quarter Results and Provides Corporate Update

Tigris Trial Enrollment at 135 PatientsStrengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter ended September 30, 2024, and provided a corporate update. Spectral has continued its significant progress throughout t

GlobeNewswire 5 months ago

EDTXF
Spectral Medical Provides October Tigris Trial Update

• 135 patients enrolled TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment continues for 202

GlobeNewswire 6 months ago

EDTXF
Those who invested in Spectral Medical (TSE:EDT) three years ago are up 122%

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Simply Wall St. 6 months ago

EDTXF
Spectral Medical Provides September Tigris Trial Update

• 132 patients enrolled TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment continues for 202

GlobeNewswire 7 months ago

EDTXF
Spectral Medical Provides August Tigris Trial Update

Management provides view on recently announced Vantive-Carlyle Group transactionTORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shoc

GlobeNewswire 8 months ago

EDTXF

BAX

CG
Spectral Medical’s revenue up 54% as company eyes Tigris trial completion

Spectral is already making plans for post FDA-approval, partnering with Baxter for commercialisation duties.

Clinical Trials Arena 8 months ago

EDTXF
Spectral Medical Second Quarter 2024 Earnings: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023)

Spectral Medical ( TSE:EDT ) Second Quarter 2024 Results Key Financial Results Revenue: CA$471.0k (up 54% from 2Q...

Simply Wall St. 8 months ago

EDTXF

Performance Overview

Return	EDT.TO	S&P/TSX Composite index (^GSPTSE)
YTD	+68.00%	+3.70%
1-Year	+69.70%	+14.45%
3-Year	+194.74%	+29.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Spectral Medical Inc. (EDT.TO)

Spectral Medical Announces First Quarter and Provides Corporate Update

Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive

Spectral Medical Completes Tigris Trial Enrollment

Spectral Medical Full Year 2024 Earnings: Beats Expectations

Spectral Medical Swing to Q4 Loss, Revenue Advances

Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update

Spectral Medical Nearing End of Tigris Trial Patient Enrollment

Spectral Medical Provides February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Provides December Tigris Trial Update

Spectral Medical Provides November Tigris Trial Update

Spectral Medical Third Quarter 2024 Earnings: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023)

Hurricane Helene delays Spectral Medical’s confirmatory trial enrolment

Spectral Medical Announces Third Quarter Results and Provides Corporate Update

Spectral Medical Provides October Tigris Trial Update

Those who invested in Spectral Medical (TSE:EDT) three years ago are up 122%

Spectral Medical Provides September Tigris Trial Update

Spectral Medical Provides August Tigris Trial Update

Spectral Medical’s revenue up 54% as company eyes Tigris trial completion

Spectral Medical Second Quarter 2024 Earnings: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023)

Performance Overview